Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy.

OBJECTIVE A minor allele variant (rs3798220) of apolipoprotein(a) has been reported to be associated with elevated plasma lipoprotein(a) [Lp(a)] and increased cardiovascular risk. We investigated whether this allele was associated with elevated Lp(a) and cardiovascular risk in the Women's Health Study, a randomized trial of low-dose aspirin, and whether aspirin reduced cardiovascular risk in minor allele carriers. METHODS AND RESULTS Genotypes of rs3798220 were determined for 25,131 initially healthy Caucasian participants. Median Lp(a) levels at baseline were 10.0, 79.5, and 153.9mg/dL for major allele homozygotes, heterozygotes, and minor allele homozygotes, respectively (P<0.0001). During the 9.9 years of follow-up, minor allele carriers (3.7%) in the placebo group had twofold higher risk of major cardiovascular events than non-carriers (age-adjusted hazard ratio (HR)=2.21, 95% CI: 1.39-3.52). Among carriers, risk was reduced more than twofold by aspirin: for aspirin compared with placebo the age-adjusted HR was 0.44 (95% CI: 0.20-0.94); risk was not significantly reduced among non-carriers (age-adjusted HR=0.91, 95% CI: 0.77-1.08). This interaction between carrier status and aspirin allocation was significant (P=0.048). CONCLUSIONS In the Women's Health Study, carriers of an apolipoprotein(a) variant had elevated Lp(a), doubled cardiovascular risk, and appeared to benefit more from aspirin than non-carriers.

[1]  R. Simari,et al.  Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. , 2001, Blood.

[2]  H. Hobbs,et al.  Lipoprotein(a): intrigues and insights. , 1999, Current opinion in lipidology.

[3]  P. Ridker,et al.  Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. , 2006, JAMA.

[4]  C. Ehnholm,et al.  Single nucleotide polymorphisms in exons of the apo(a) kringles IV types 6 to 10 domain affect Lp(a) plasma concentrations and have different patterns in Africans and Caucasians. , 2001, Human molecular genetics.

[5]  M. Boffa,et al.  Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. , 2004, Clinical biochemistry.

[6]  Thomas Lumley,et al.  Association of Gene Variants With Incident Myocardial Infarction in the Cardiovascular Health Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  K. Aihara,et al.  Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. , 2002, Clinical chemistry.

[8]  M. Koschinsky,et al.  Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside , 2003, Current opinion in lipidology.

[9]  M. Myerson,et al.  High Levels of Lp(a) With a Small Apo(a) Isoform Are Associated With Coronary Artery Disease in African American and White Men , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[10]  G. Franceschini,et al.  Plasma lipoprotein(a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. , 1996, Stroke.

[11]  F. Kronenberg,et al.  Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. , 1999, Circulation.

[12]  G. Lippi,et al.  Lipoprotein(a): Structure, Measurement and clinical significance. , 1994 .

[13]  N. Rifai,et al.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). , 2000, Clinical chemistry.

[14]  H. Azuma,et al.  Aspirin Reduces Apolipoprotein(a) (Apo(a)) Production in Human Hepatocytes by Suppression of Apo(a) Gene Transcription* , 1999, The Journal of Biological Chemistry.

[15]  G. Utermann,et al.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. , 1987, The Journal of clinical investigation.

[16]  M. Koschinsky,et al.  Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). , 1995, Biochemistry.

[17]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[18]  E. Topol,et al.  A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[19]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[20]  P. Loehrer.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women's Health Study: A Randomized Controlled Trial , 2006 .

[21]  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women , 2005 .

[22]  M. Boffa,et al.  Inhibition of Plasminogen Activation by Lipoprotein(a) , 2003, Journal of Biological Chemistry.

[23]  M. Koschinsky,et al.  Effects of lipoprotein(a) on the binding of plasminogen to fibrin and its activation by fibrin-bound tissue-type plasminogen activator. , 1994, Chemistry and physics of lipids.

[24]  F. Kronenberg,et al.  Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? , 2004, Kidney international.

[25]  E. Brilakis,et al.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. , 2005, The New England journal of medicine.

[26]  M. Koschinsky,et al.  Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance. , 2004, Biochemistry.

[27]  RoryCollins,et al.  Lipoprotein(a) and Coronary Heart Disease , 2000 .

[28]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[29]  Nader Rifai,et al.  Handbook of Lipoprotein Testing , 2001 .

[30]  R. Ramakrishnan,et al.  Lipoprotein(a): an elusive cardiovascular risk factor. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  R. Junker,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[32]  Paul M. Ridker,et al.  Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women , 2007 .

[33]  J. Breslow,et al.  Plasma Ip(a) concentration is inversely correlated with the ratio of Kringle IV/Kringle V encoding domains in the apo(a) gene. , 1989, The Journal of clinical investigation.